Altimmune stock dropped 9% after reporting a wider-than-expected Q4 loss of $0.27 per share. Despite the miss, the company stated its $340 million cash balance provides an operating runway into 2028. The CFO confirmed they are being strategic in securing capital for the late-stage MASH trial. Data for its Alcohol Use Disorder study is expected in Q3 2026.